| Description | Aplodan (creatinol-O-phosphate) exhibits antiischemic and antiarrhythmic capacity and protective action on the cell membrane. Aplodan can be used in research on the ischemic heart or ischemic heart disease with persistent ventricular premature beats. |
| Synonyms | Nergize, Creatinolfosfate, 磷酸肌肉醇, creatinol-O-phosphate, Creatinolfosfate, Creatinol Phosphate |
| molecular weight | 197.13 |
| Molecular formula | C4H12N3O4P |
| CAS | 6903-79-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: Slightly soluble |
| References | 1. Godfraind T, Saleh MM. Action of creatinol-O-phosphate on the contractility changes evoked by hypoxia and ischemia in rat isolated heart. Arzneimittelforschung. 1984;34(9):968-72. PubMed PMID: 6542374. 2. Ferrini R, Miragoli G. Protective effect of creatinol O-phosphate (COP) on some experimental arrhythmias in vitro and in vivo. Arzneimittelforschung. 1979;29(9a):1475-7. PubMed PMID: 575497. 3. Godfraind T, Ghysel-Burton J, Merlo L. The action of creatinol 0-phosphate on the inotropic effect of isoprenaline in isolated rat atria and in anesthetized dogs. Arzneimittelforschung. 1979;29(9a):1465-7. PubMed PMID: 575493. 4. Marzo A, Ghirardi P. Pharmacological and toxicological properties of creatinol O-phosphate. A review. Arzneimittelforschung. 1979;29(9a):1449-52. Review. PubMed PMID: 395957. |